Document Detail

Immune therapy in type 1 diabetes mellitus.
MedLine Citation:
PMID:  23296174     Owner:  NLM     Status:  Publisher    
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder directed against the β cells of the pancreatic islets. The genetic risk of the disease is linked to HLA-DQ risk alleles and unknown environmental triggers. In most countries, only 10-15% of children or young adults newly diagnosed with T1DM have a first-degree relative with the disease. Autoantibodies against insulin, GAD65, IA-2 or the ZnT8 transporter mark islet autoimmunity. These islet autoantibodies may already have developed in children of 1-3 years of age. Immune therapy in T1DM is approached at three different stages. Primary prevention is treatment of individuals at increased genetic risk. For example, one trial is testing if hydrolyzed casein milk formula reduces T1DM incidence in genetically predisposed infants. Secondary prevention is targeted at individuals with persistent islet autoantibodies. Ongoing trials involve nonautoantigen-specific therapies, such as Bacillus Calmette-Guérin vaccine or anti-CD3 monoclonal antibodies, or autoantigen-specific therapies, including oral and nasal insulin or alum-formulated recombinant human GAD65. Trial interventions at onset of T1DM have also included nonautoantigen-specific approaches, and autoantigen-specific therapies, such as proinsulin peptides. Although long-term preservation of β-cell function has been difficult to achieve in many studies, considerable progress is being made through controlled clinical trials and animal investigations towards uncovering mechanisms of β-cell destruction. Novel therapies that prevent islet autoimmunity or halt progressive β-cell destruction are needed.
Ake Lernmark; Helena Elding Larsson
Related Documents :
23861104 - Prevalence of type 2 diabetes in argentina 1979-2012.
24225334 - Improving the economic value of photographic screening for optical coherence tomography...
23531954 - The diabetes initiative of south carolina and the 18th annual diabetes fall symposium f...
23963254 - The relationship between county-level contextual characteristics and use of diabetes ca...
17685164 - Optimising glycaemic control for patients starting insulin therapy.
8732714 - Evolution, risk factors, and prognostic implications of albuminuria in niddm.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-08
Journal Detail:
Title:  Nature reviews. Endocrinology     Volume:  -     ISSN:  1759-5037     ISO Abbreviation:  Nat Rev Endocrinol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500078     Medline TA:  Nat Rev Endocrinol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Lund University, Department of Clinical Sciences, Jan Waldenströms gata 35, Skåne University Hospital SUS, SE-20502 Malmö, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coming full circle in diabetes mellitus: from complications to initiation.
Next Document:  Thyroid in 2012: Advances in thyroid development, hormone action and neoplasia.